Refine your search
Collections
Co-Authors
Journals
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Vaidya, A. D. B.
- The Effect of Vitamin K2-7 in Peripheral Neuropathy Due to Vitamin B12 Deficiency and Diabetes Mellitus: a Preliminary Study
Abstract Views :272 |
PDF Views:0
Authors
V. K. Kulkarni
1,
D. U. Upase
2,
Y. A. Dound
3,
S. S. Jadhav
3,
A. A. Bhave
4,
D. S. Mehta
3,
A. D. B. Vaidya
4
Affiliations
1 Department of Haematology, B. Y. L. Nair Ch. Hospital, Dr. A. L. Nair Road, Mumbai Central, 7, Shefalee, Makarand Society, Veer Savarkar Marg, Mahim, Mumbai - 400016, IN
2 Department of Haematology, B. Y. L. Nair Ch. Hospital, Dr. A. L. Nair Road, Mumbai Central, Mumbai, IN
3 Viridis BioPharma Pvt. Ltd., V. N. Purav Marg, Chunabhatti, Mumbai, IN
4 ICMR Advance Centre of Reverse Pharmacology in Traditional Medicine, Medical Research Center-Kasturba Health Society, Mumbai, IN
1 Department of Haematology, B. Y. L. Nair Ch. Hospital, Dr. A. L. Nair Road, Mumbai Central, 7, Shefalee, Makarand Society, Veer Savarkar Marg, Mahim, Mumbai - 400016, IN
2 Department of Haematology, B. Y. L. Nair Ch. Hospital, Dr. A. L. Nair Road, Mumbai Central, Mumbai, IN
3 Viridis BioPharma Pvt. Ltd., V. N. Purav Marg, Chunabhatti, Mumbai, IN
4 ICMR Advance Centre of Reverse Pharmacology in Traditional Medicine, Medical Research Center-Kasturba Health Society, Mumbai, IN
Source
The Indian Practitioner, Vol 66, No 10 (2013), Pagination: 625-629Abstract
Objective: To evaluate the activity and tolerability of Vitamin K2-7 (MK-7) in a series of patients with peripheral neuropathy due to vitamin B12 deficiency and/or diabetes mellitus.Material and Methods: An open labeled clinical study was conducted in 30 patients presenting with peripheral neuropathy and suffering from either megaloblastic anaemia (viamin B12 deficient) and/ or diabetes mellitus. Vitamin B12 levels in blood were estimated at baseline and during therapy. Vitamin K2-7 capsules (100 mcg/capsule, twice a day) was given orally for 8 weeks. Patients kept a regular record of the intensity of the symptoms during the baseline and throughout the study. Symptoms included tingling and numbness along with weakness, fatigue and cramps. The intensity of the symptoms was assessed on a Visual Analog Scale (VAS). They were followed up to 8 weeks. Blood biochemical and organ function tests were studied at the baseline, at the fourth week and at the end of the eight week. Prior to the study Ethics Committee Approval was obtained from the Ethics Committee of T. N. M. C.&B. Y. L. Nair Ch. Hospital. The trial was registered with Clinical Trial Registry of India (CTRI). (CTRI/2012/08/002930). Informed written consent was obtained from the patients before enrollment.
Results: Depending on the basal VAS score the patients were divided in a moderate group and a severe group. The moderate group had VAS score of 6-8 and the severe group had a VAS score of 8-9. By the end of eight week, the VAS score in both the groups was reduced to 1-2. The intensity specifically of tingling and numbness has reduced to a much greater extent. It was of interest to observe that ten out of 23 patients of Vitamin B12 deficiency group had residual neuropathic symptoms in-spite of adequate levels of Vitamin B12 following vitamin B12 administration. The residual neuropathic symptom score reduced following Vitamin K2-7 therapy. Vitamin K2-7 was well tolerated clinically and found to be safe as per the organ functions in all the patients. No adverse events were reported during the period of therapy.
Conclusion: This preliminary study has shown that vitamin K2-7 at a dose of 100 mcg twice a day for 8 weeks was well tolerated and safe with a therapeutic activity for the symptoms of peripheral neuropathy. However, the therapeutic efficacy needs to be evaluated further in a larger sample size, with a placebo controlled randomised double blind trial.
Keywords
Vitamin K2-7, Diabetes Mellitus, Megaloblastic Anaemia, Peripheral Neuropathy, Reverse Pharmacology.
- Cow's Milk:Nutritional Relevance beyond its Intolerance and Allergies
Abstract Views :277 |
PDF Views:1
Authors
Affiliations
1 Medical Research Centre, Kasturba Health Society, 17, Khandubhai Desai Road, Vile Parle (W), Mumbai - 400056, IN
2 Integrative Nutrition and Ayurceuticals, Medical Research Centre, Kasturba Health Society, 17, Khandubhai Desai Road, Vile Parle (W), Mumbai - 400056, IN
3 Division of Endocrine and Metabolic Disorders, Medical Research Centre, Kasturba Health Society, 17, Khandubhai Desai Road, Vile Parle (W), Mumbai - 400056, IN
1 Medical Research Centre, Kasturba Health Society, 17, Khandubhai Desai Road, Vile Parle (W), Mumbai - 400056, IN
2 Integrative Nutrition and Ayurceuticals, Medical Research Centre, Kasturba Health Society, 17, Khandubhai Desai Road, Vile Parle (W), Mumbai - 400056, IN
3 Division of Endocrine and Metabolic Disorders, Medical Research Centre, Kasturba Health Society, 17, Khandubhai Desai Road, Vile Parle (W), Mumbai - 400056, IN
Source
The Indian Practitioner, Vol 70, No 4 (2017), Pagination: 29-34Abstract
Since antiquity mankind has been nourished on milk, a rich source of good quality protein, lactose, fats, vitamins and minerals. However, the health benefits of milk vs. its probable adverse health effects are being debated. This has triggered a trend of completely excluding milk from diet. This is of concern, especially in India, where milk has been a key dietary component especially for children and only source of first class proteins for vegetarians.
This article reviews current scientific literature on the effect of milk on health and disease. Original articles and review articles from high impact biomedical journals from PubMed, official documents released by the Govt. of India available from Google and diverse social media were extensively studied including Wikipedia articles and blogs from various sites. The prime issues; viz., milk allergy, lactose intolerance, adulterants and recently A1 milk, questioning the health benefits of milk are discussed and possible ways to overcome the problems are suggested.
Keywords
Cow Milk, Nutrition, Milk Allergy, A1-β Casein, Milk Intolerance, Indigenous Cows.References
- Chawre SV, Shinde VS, Kabra PR et al. Therapeutic and nutritional significance of Dugdha (Milk) with reference to cow milk. Int. Res. J. Pharm. 2014;5(6): 449-453.
- National Workshop on Gavya-chikitsa for Health. Organized by MRC-KHS, Mumbai and Holistic Health Foundation, Hyderabad, 29-30th June 2013.
- Symposium: Gavyachikitsa: Myths or Reality Indian Pharmacology Society (IPSCON 2015), Saurashtra University, Rajkot, Gujarat 18-20th December 2015.
- Haug A, Haustmark AT, Harstad OM. Bovine milk in human nutrition – a review. Lipids Health Dis. 2007; 6: 25.
- Nutrient content of milk varieties. http://milkfacts.info/Nutrition%20Facts/Nutrient%20Content.htm
- Bainbridge ML, Cersosimo LM, WrightA-D G, Kraft J. Content and composition of branched - chain fatty acids in bovine milk are affected by lactation stage and breed of dairy cow. Plos ONE 11(3)e0150386. doi:10.1371/journal. pone.0150386
- Agnihotri MK, Rajkumar V. Effect of Breed, Parity and Stage of Lactation on Milk Composition of Western Region Goats of India. International Journal of Dairy Science. 2007;2: 172-177.
- Thorning TK , Raben A, Tholstrup T ,SoedamahMuthu S S et al. Milk and dairy products: good or bad for human health? An assessment of the totality of scientific evidence. AdvNutr. 2016;7:1026-1040.
- Riserus U, Marklund M. Milk fat biomarkers and cardiometabolic disease. Curr Opin Lipidol. 2017;28:46-51
- Kim SH, Kim WK, Kang MH. Effect of milk and milk products consumption on physical growth and bone mineral density in Korean adolescents. Nutr Res Pract. 2013;7(4):309-314.
- Naik S, Bhide V, Babhulkar A, Mahalle N et al. Daily milk intake improves vitamin B-12 status in young vegetarian Indians: an intervention trial Nutrition Journal. 2013;12:136. doi:10.1186/1475-2891-12-136.
- Barr SI, McCarron DA, Heaney RP, Hughes BD et al. Effects of increased consumption of fluid milk on energy and nutrient intake, body weight, and cardiovascular risk factors in healthy older adults. J. Am Dietetic Association. 2000;100(7):810-817.
- Lien do TK, Nhung BT, Khan NC, Hop le T, Nga NT et al. Impact of milk consumption on performance and health of primary school children in rural Vietnam. Asia Pac J ClinNutr.2009;18 (3):326-334.
- Rahmani K, Djazayery A, Habibi MI, Heidari H, Dorosti-Motlagh AR et al. Effects of daily milk supplementation on improving the physical and mental function as well as school performance among children: results from a school feeding program. Res Med Sci. 2011;16(4): 469–476.
- Choi IY, Denney DR, Spaeth K, Nast O, Ptomey L et al. Dairy intake is associated with brain glutathione concentration in older adults. Am J Clin Nutr. 2015;101:287-93.
- Elwood PC, Givens DI, Beswick AD, Fehily AM et al. The survival advantage of milk and dairy consumption: an overview of evidence from cohort studies of vascular diseases, diabetes and cancer. J Am Coll Nutr. 2008;27(6): 723S–734S.
- Jakubowicz D, Froy O. Biochemical and metabolic mechanisms by which dietary whey protein may combat obesity and Type 2 diabetes. J Nutr Biochem. 2013; 24: 1–5.
- Parodi PW. Conjugated linoleic acid and other anticarcinogenic agents of bovine milk fat. A symposium on: A BOLD NEW LOOK AT MILK FAT. J Dairy Sci. 1999; 82:1339-1349.
- Nantapo CTW, Muchenje V, Hugo A. Atherogenicity index and health-related fatty acids in different stages of lactation from Friesian, Jersey and Friesian x Jersey cross cow milk under a pasture-based dairy system. Food Chemistry. 2014;146:127-133.
- Korhonen H, Pihlanto A. Technological Option for the Production of health-promoting proteins and peptides derived from milk and colostrum. Curr Phramceutical Design. 2007;13:829-843.
- Korhonen HJ. Production and properties of healthpromoting proteins and peptides from bovine colostrum and milk. Cell Mol Biol. 2012;58(1):26-38.
- Sampson HA. Utility of food-specific IgE concentrations in predicting symptomatic food allergy. J Allergy Clin Immunol. 2001;107(5):891-896.
- Fiocchi A, Brozek J, Schu¨nemann H, BahnaSL, von Berg A, Beyer K et al.World Allergy Organization (WAO) Diagnosis and rationale for action against cow’s milk allergy (DRACMA) guidelines. Pediatr Allergy Immunol. 2010;21Suppl 21:1-125.
- Hochwallner H, Schulmeister U, Swoboda I, Spitzauer S et al. Cow’s milk allergy: From allergens to new forms of diagnosis, therapy and prevention. Methods. 2014; 66:22-33.
- Skripak JM, Matsui EC, Mudd K, Wood RA. The natural history of IgE-mediated Cow’s milk allergy. J. Allergy Clin Immunol. 2007;120(5):1172-7.
- Matthews SB, Waud JP, Roberts AG et al. Systemic lactose intolerance: a new perspective on an old problem. Postgraduate Medical Journal. 2005;81:167-173.
- Deng Y, Misselwitz B, Dai N, Fox M. Lactose intolerance in adults:Biological mechanism and dietary management. Nutrients. 2015;7(9):8020-8035.
- Silanikove N, Leitner G, Merin U. The Interrelationships between lactose intolerance and the modern dairy industry: Global perspectives in evolutional and historical backgrounds. Nutrients. 2015;7:7312-7331.
- Tandon RK, Joshi YK, Singh DS, Narendranathan M, Balakrishnan V et al. Lactose intolerance in North and South Indians. Am J ClinNutr. 1981;34(5):943-6.
- Babu J, Kumar S, Babu P, Prasad JH et al. Frequency of lactose malabsorption among Healthy southern and northern Indian populations by genetic analysis and lactose hydrogen breath and tolerance tests. Am J ClinNutr. 2010;91(1):140-6.
- Ghoshal UC, Kumar S, Misra A, Mittal B. Lactose malabsorption diagnosed by 50-g dose is inferior to assess clinical intolerance and to predict response to milk withdrawal than 25-g dose in an endemic area. J Gastroenterol Hepatol. 2013;28(9):1462-8.
- Usai-Satta P, Scarpa M, Oppia F, Cabras F. Lactose malabsorption and intolerance: What should be the best clinical management? World Journal of Gastrointestinal Pharmacology and Therapeutics. 2012;3(3):29-33.
- M¹dry E, Fidler E, Walkowiak J. Lactose intolerance – current state of knowledge. Acta Sci. Pol., Technol. Aliment. 2010;9(3):343-350.
- Yvan V. Lactose intolerance. Asia Pac J ClinNutr. 2015;24(Suppl 1):S9-S13 S9.
- Misselwitz B, Pohl D, Frühauf H, Fried M, Vavricka SR et al. Lactose malabsorption and intolerance: pathogenesis, diagnosis and treatment. United European Gastroenterol J. 2013;1(3):151–159.
- Swin Burn B. Beta casein A1 and A2 in milk and human health. Report to New Zealand Food Safety Authority. 2004 www.foodsafety.govt.nz/elibrary/ industry/beta_casein-report_reviews.pdf
- Kaminski S, Cieslinska A, Kostyra E. Polymorphism of bovine beta-casein and its potentialeffect on human health. Journal of Applied Genetics. 2007;48(3):189-198.
- Ng-Kwai-Hang, KF, F Grosclaude. Genetic polymorphism of milk proteins. In Fox PF and McSweeney PLH (eds), Advanced Dairy Chemistry, Chapter 16:737-814. Kluwer Academic/Plenum Publishers, New York. Print, 2002.
- Pal S, Woodford K, Kukuljan S, Ho S. Milk Intolerance, Beta-Casein and Lactose. Nutrients. 2015;7(9):7285-7297.
- Noni ID, FitzGerald RJ, Korhonen HJT, Roux YL, Livesey CT et al. Review of the potential health impact of â-casomorphins and related peptides. Report of the DATEX Working Group on â-casomorphins. European Food Safety Authority, 2009 https://www.efsa.europa.eu/en/efsajournal/pub/231r
- Mohammad RH, Kapilaa R, Shandilyaa UK,Kapilaa S. Impact of Milk derived â-casomorphins on Physiological functions and trends in research: A Review. Int J Food Properties. 2014;17:1726-1741.
- Ganapathy, V, S Miyauchi. Transport systems for opioid peptides in mammalian tissues. AAPS J. 2005;7(4):E852-6.
- Parashar A, Saini RK. A1 milk and its controversy-a review. Int J Bioassay. 2015;4.12: 4611-4619.
- Truswell AS. The A2 milk case: a critical review. Eu J of ClinNutr. 2005;59:623-631.
- De S, Paradkar P, Vaidya A. Indian breed cow milk – power house of health, 2015. http://www.fnbnews.com/article/print.asp?articleid=37729 https://www.researchgate.net/publication/281430281
- Zaitlin P, Dwyer J, Gleason GR. Mistaken beliefs and the facts about milk and dairy foods. Nutrition Today. 201348(3):135–143.
- Deth R, Clarke A, Ni J, Trivedi M. Clinical evaluation of glutathione concentrations after consumption of milk containing different subtypes of â-casein: results from a randomized, cross-over clinical trial. Nutrition Journal. 2015;15:82.
- Mishra BP, Mukesh M, Prakash B, Sodhi M, Kapila R. Kishore A et al. Status of milk protein â-casein variants among Indian milch animals. Indian J of Animal Sciences.2009;79(7):722-5.
- Govt. of India. 19th Livestock Census -2012 – All India Report. http://dahd.nic.in/dahd/WriteReadData/ Livestock.pdf
- Vitamin K2-7, a Promising Solution to Peripheral Neuropathy aroused due to Multiple Myeloma Treatment
Abstract Views :270 |
PDF Views:0
Authors
Affiliations
1 Empire Centre Haematology & Oncology Specialty Clinic, Mumbai, IN
2 Synergia Life Sciences Pvt. Ltd., Mumbai, IN
3 KHS MRC, Mumbai, IN
4 Gujarat Cancer Research Institute, Ahmedabad, IN
1 Empire Centre Haematology & Oncology Specialty Clinic, Mumbai, IN
2 Synergia Life Sciences Pvt. Ltd., Mumbai, IN
3 KHS MRC, Mumbai, IN
4 Gujarat Cancer Research Institute, Ahmedabad, IN
Source
The Indian Practitioner, Vol 72, No 1 (2019), Pagination: 16-20Abstract
Objective: A large number of patients with Multiple Myeloma (MM) develop Peripheral Neuropathy (PN). This is either consequent upon iatrogeny with prolonged therapy or as a part of the disease. The persistence of disabling PN, during therapy, often compels the physician to a reduction in the dose of the primary agents or their total discontinuation or replacement. Our previous study with Vitamin K2-7 has shown therapeutic activity in patients with diabetic neuropathy and/or with vitamin B12 deficiency. An anecdotal observation of considerable relief of PN in an MM patient, after chemotherapy, prompted us for this observational study. The present brief communication reports the ameliorative potential of Vitamin K2-7 in the management of iatrogenic PN in MM.
Material and Methods: This communication describes a case-series of seventeen patients with iatrogenic PN for MM. Vitamin K2-7 was given orally to patients who complained of PN till 4 chemotherapy cycles and followed up to 5th chemotherapy cycle. Symptoms included tingling, numbness along with burning sensation, fatigue and cramps. This study was approved by an independent ethics committee.
Results: Twelve out of seventeen patients reported relief. Vitamin K2-7 had allowed these twelve patients continuation of treatment for MM, without any reduction of dosage or temporary discontinuation of treatment. Three patients had discontinued the MM treatment and two had discontinued Vitamin K2-7 on their own after they did not find any marked relief.
Conclusions: This preliminary observational study, to our knowledge, suggests for the first time that Vitamin K2-7 has an ameliorative potential for relief of iatrogenic PN in MM patients. The positive directionality of the outcome necessitates a larger study with an objective assessment of PN with Nerve Conduction Velocity and with the use of validated Visual Analog Scale for subjective features of PN.
Keywords
Multiple myeloma, Vitamin K2-7, Peripheral Neuropathy, Drug-induced Neuropathy.References
- Dimopoulos MA and Terpos E. Multiple myeloma. Ann Oncol 2010;21: vii143-50.
- Rajkumar SV and Kumar S. Multiple myeloma: Diagnosis and treatment. Mayo Clinic 2016;91:101-19.
- Martin TG. Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib. Oncology 2013;27:4-10.
- E. Terpos et al. European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. Haematologica. 2015; 100(10): 1254:66.
- Morawska M, Grzasko N, Kostyra M et al. Therapy-related peripheral neuropathy in multiple myeloma patients. Hematol Oncol 2015;33:113–9.
- Fallon MT, Storey DJ, Krishan A et al. Cancer treatment-related neuropathic pain: proof of concept study with menthola TRPM8 agonist. Support Care Cancer 2015;23:2769–77.
- Kulkarni VK, Upase DP, Dound YA et al. The effect of vitamin K2-7 in peripheral neuropathy due to Vitamin B12 deficiency and/or diabetes mellitus: A Preliminary Study. The Indian Practioner 2013;66:625-9.
- Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone (pom/dex) is highly effective therapy in relapsed multiple myeloma. J Clin Oncol 2009;27:5008–14.
- Schey S and Ramasamy K. Pomalidomide therapy for myeloma. Expert Opin Investig Drugs 2011;20:691–700.
- Cata JP, Weng HR, Burton AW, et al. Quantitative sensory findings in patients with bortezomib-induced pain. J Pain 2007;8:296–306.
- Idia S, Wakabayashi M, Tsukasaki K, et al. Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma. Cancer sci 2018;109:1552-61.
- McCullough KB, Hobbs MA, Abeykoon JP et al. Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies. Curr Hematol Maliq Rep 2018;13:114-24.
- Terpos E, Suzan F and Goldschmidt H. Going the distance: Are we losing patients along the multiple myeloma treatment pathway? Critical Reviews in Oncology/Hematology. Volume 126, June 2018, Pages 19-23.
- Windebank AJ and Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008;13:27–46.
- Vaidya ADB, Mehta DS, de Souza A, Vaidya RA. Treatment of Human Disease Conditions and Disorders using Vitamin K analogues and Derivatives. PCT/IN2008/000465, Jul 2008.
- Mehta DS, Vaidya RA, Dound YA et al. Therapeutic Activity and Safety of Vitamin K 2-7 in Muscle Cramps: An Interventional Case- Series. The Indian Practitioner 2010 May: 287-291.
- Ravishankar B, Dound YA, Mehta DS et al. Safety assessment of menaquinone-7 for use in human nutrition. J Food Drug Anal 2015;23:99-108.
- Mehta DS, Dound YA, Jadhav SS et al. A novel potential role of Vitamin K2‑7 in relieving peripheral neuropathy. J Pharmacol Pharmacother 2018;9.DOI: 10.4103/jpp.JPP_72_18.
- Ayurvedic Dravyaguna (Pharmacological) Correlates with Biological Plausibility for Antidiabetic activity of Eujenia jambolana Linn
Abstract Views :203 |
PDF Views:0
Authors
Affiliations
1 KHS-MRC, Mumbai and Ph D Scholar. The Centre for Ayurveda Biology and Holistic Nutrition, The University of Trans-disciplinary Health Sciences and Technology TDU, Bengaluru, IN
2 Div of Endocrinology and Metabolic disorder, KHS-MRC, Mumbai, IN
3 The Centre for Ayurveda Biology and Holistic Nutrition, The University of Trans-disciplinary Health Sciences and Technology, TDU Bengaluru, IN
4 Clinical Research and Integrative Medicine, KHS-MRC, Mumbai, IN
5 KHS-MRC, Mumbai and Emeritus Professor, The University of Trans-disciplinary Health Sciences and Technology, IN
1 KHS-MRC, Mumbai and Ph D Scholar. The Centre for Ayurveda Biology and Holistic Nutrition, The University of Trans-disciplinary Health Sciences and Technology TDU, Bengaluru, IN
2 Div of Endocrinology and Metabolic disorder, KHS-MRC, Mumbai, IN
3 The Centre for Ayurveda Biology and Holistic Nutrition, The University of Trans-disciplinary Health Sciences and Technology, TDU Bengaluru, IN
4 Clinical Research and Integrative Medicine, KHS-MRC, Mumbai, IN
5 KHS-MRC, Mumbai and Emeritus Professor, The University of Trans-disciplinary Health Sciences and Technology, IN
Source
The Indian Practitioner, Vol 73, No 2 (2020), Pagination: 26-31Abstract
Eujenia jambolana Linn (Jambu / Black plum; EjL) was found to be a frequently used medicinal plant in our earlier study of Marketed Ayurvedic Antidiabetic Formulations. Ayurvedic dravyaguna rationale and Biological Plausibility (BP) of EjL for anti-diabetic activity are currently reviewed in view of developing a new drug candidate for type 2 diabetes mellitus using Reverse Pharmacology. Classical and emerging Ayurvedic literature as well as modern pharmacological literature of EjL were reviewed here for Ayurvedic properties and biological plausibility foranti-diabetic potentials.Keywords
Indian Medicinal Plants, Dravyaguna Rationale, Biological Plausibility, Diabetes, Ayurvedic Pharmacoepidemiology, Jambu, Eugenia jambolana.References
- Raut A A. Integrative endeavor for renaissance in Ayurveda. J Ayurveda Integr Med. 2011; 2(1): 5–8.
- Vaidya, RA. Vaidya ADB, Patwardhan B, Tillu G, Rao Y. Ayurvedic Pharmacoepidemiology: A proposed New Descipline. JAPI.2003;51:528
- Vaidya RA. Observational Therapeutics: Scope, Challenges, and organizations. Journal of Ayurveda & Integrative Medicine.2011;2: 165-169.
- Vaidya ADB. Reverse Pharmacology Correlates of Ayurvedic Drug Action. Ramnath Chopra Award Oration. Ind J Pharmacol.2006; 38: 311-315
- Patwardhan B. AyuGenomics–Integration for customized medicine. Indian J. Nat. Prod. Resour.2003; 19: 16–23
- Padma Venkat. Reverse Pharmacognosy: A novel strategy to standardize ISM drugs.https://www.yumpu.com/en/document/view/35594143/reverse-pharmacognosy-a-novel-strategy-to-standardize-crism
- Vaidya ADB. Nutraceuticals, Naturals and Nutritionals-A Discovery Path from AyurvedaNuffood. 2013
- https://www.cdac.in/index.aspx?id=hi_dss_ayusoft_n 9. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008 Nov;4(11):682-90. doi: 10.1038/nc hembio.118.
- Satyavati GV, Dwarakanath C, Tripathi SN. Experimental studies on the hypocholesterolemic effect of Commiphoramukul Engl. (Guggul). 1969. Indian J Med Res. 2013 Feb;137(2):14 p following p403
- Nabar N, Vaidya R, Narayana DB, Raut A, Shah S, Patwardhan B,et al. Marketed Ayurvedic antidiabetic formulations: Labelling, drug Information and branding. The Indian Pract 2013; 66:631‑41.
- Gajarmal AA, Rath SK. Antidiabetic Activity of IME-9, Research Formula By CCRAS - A Review. Journal of Drug Research 2016; 5(2): 41-58
- Mayaram Sunderji Vaidya
- Vaidya AB, Antarkar DS, Joshi B.S Traditional Remedies for diabetes Mellitus: Trails, Trials and Trilateral Quest. Diabetes Bulletin 1989; 186-191
- GogteVM. Ayurvedic Pharmacology and Therapeutic Uses of Medicinal Plants (Dravyagunavidnyan). Mumbai: Bhavan’s SPARC; 2000.
- Acharya JT. Editor of ChakrapaniTika by Chakradata of Charaka Samhita, Chaukhambha Sanskrit Sansthan, Varanasi, 5th Ed,2001;211-16 and 444-50(Charaknidan 4 & Charakchikitsa 6)
- Vaidya ADB, Nabar NS, Vaidya RA. Current Status of Indigenous Drugs and Alternative Medicine in the Management of Diabetes Mellitus. Revised chapter 45 in Volume I of RSSDI Textbook of Diabetes. ED by Tripathy BB, Chandalia HB and team. 3rd Ed 2014 .
- Terry, Luthar et al. Smoking and Health: Report of the advisory committee to Surgeon General of the United States. U-23 Department of Health,Education and welfare. Public Health Service. Publicationno 1103.1964 (https : // profiles .nlm .nih. gov/ps /retrieve /Resource Metadata /NNBBMQ).
- Fedak K M, BernalA, Capshaw Z A, and Gross S. Applying the Bradford Hill criteria in the 21st century: how data integration has changed causal inference in molecular epidemiology. Emerg Themes Epidemiol. 2015; 12: 14.
- Gamalielsson J., Nilsson P., Olsson B. A GO-Based Method for Assessing the Biological Plausibility of Regulatory Hypotheses. In: Alexandrov V.N., van Albada G.D., Sloot P.M.A., Dongarra J. (eds) Computational Science – ICCS 2006. ICCS 2006. Lecture Notes in Computer Science, vol 3992. Springer, Berlin, Heidelberg.
- Sasikala SS, Karpakavalli M, Ranjithkumar D, Prakash G, Vanathi P, Mohan S. In-vitro free radical scavenging activity studies of extracts and isolated compounds of Eugenia jambolana Linn. Seeds. World journal of pharmaceutical research. 2016: 5:
- Jain A, Sharma S, Goyal M, Dubey S, Jain S, et al . Antiinflammatory activity of Syzygium Cumini leaves International Journal of Phytomedicine 2010; 2: 124-126
- Ahmed F, Chandra JNNS ,Timmaiah NV. An In Vitro Study on the inhibitory Activities of Eugenia jambolana Seeds Against Carbohydrate Hydrolyzing Enzymes. J Young Pharm. 2009;1: 317-321
- Sharma SB, Tanwar RS, Nasir A, Prabhu KM. Antihyperlipidemic effect of active principle isolated from seed of Eugenia jambolana on alloxan-induced diabetic rabbits. J Med Food. 2011;14(4):353-9.
- Bilal R, Zakaria M, Usman A, Zia A. Comparison of simvastatin with Eugenia Jambolana fruit pulp in their effects on Alanine Transferase, Aspartate Aminotransferase and Creatinine Phosphokinase levels of hyperlipidaemic rats. J Pak Med Assoc. Vol. 2011; 61(12):1190-1194
- Franca LM, Coêlho CFF, Freitas LNC, SouzaILS et al. Syzygium cumini Leaf Extract Reverts Hypertriglyceridemia via Down regulation of the Hepatic XBP-1s/PDI/MTP Axis in Monosodium L-Glutamate-Induced Obese Rats. Oxidative Medicine and Cellular Longevity.2019, Article ID 9417498
- Shukla SK, Sharma SB, Singh UR, Ahmad S, Maheshwari A, Misro M, Dwivedi S. Eugenia jambolana pre treatment prevents isoproterenol-induced myocardial damage in rats: evidence from biochemical, molecular, and histopathological studies. J Med Food. 2014 Feb; 17(2):244-53.
- Behera S R, Sekkizhar M, Sarath Babu K. Nephro-protective Effect of Aqueous Extract of Syzygium cumini Seed on Streptozotocin Induced Diabetes in Rats Int. J. Chem. & Life Sci. 2014;3 : 1285-1288
- Ribeiro RM, NetoVFP,Ribeiro KS, Vieira DA, et al. Antihypertensive Effect of Syzygium cumini in Spontaneously Hypertensive Rats Evidence-Based Complementary and Alternative Medicine. 2014, Article ID 605452
- Tanwar RS, Sharma SB, Prabhu KM. In vivo assessment of antidiabetic and antioxidative activity of natural phytochemical isolated from fruit-pulp of Eugenia jambolana in streptozotocin-induced diabetic rats. Redox Rep. 2017; 22(6):301-307.
- Rehman AA, Riaz A, Asghar MA, Raza MR, Shadab Ahmed S, Khan K. In vivo assessment of anticoagulant and antiplatelet effects of Syzygium cumini leaves extract in rabbits. BMC Complementary and Alternative Medicine.2019; 19:236
- Xu J, Liu T, Li Y, Liu W, Ding Z, Ma H, et al. Jamun (Eugenia jambolana Lam.) Fruit Extract Prevents Obesity by Modulating the Gut Microbiome in High-Fat-Diet-Fed Mice. MolNutr Food Res. 2019;63(9):e1801307.
- Chaudhary A, Bag S, Banerjee P,Chatterjee J. Wound healing efficacy of Jamun honey in diabetic mice model through re epithelialization, collagen deposition and angiogenesis. Journal of Traditional and Complementary Medicine, 2019. https://doi.org/10.1016/j.jtcme.2019.10.002
- Bijauliya RK, Alok S, Singh M and Mishra SB: Morphology, Phytochemistry and Pharmacology of Syzygium Cumini (Linn.) - An Overview. Int J Pharm Sci Res 2017; 8(6): 236071.doi: 10.13040/IJPSR.0975-8232.8(6).2360-71
- Chagas VT, França LM, Malik S, Antonio Marcus de Andrade Paes. Syzygium cumini (L.) skeels: a prominent source of bioactive molecules against cardiometabolic diseases. Front Pharmacol 2015; 6: 259
- Baliga MS, Harshith P. Bhat D, Bantwal RV Baligab,Wilson R, Palatty PL. Phytochemistry, traditional uses and pharmacology of Eugenia jambolana Lam.(black plum): A review. Food Research International.2011; 44 : 1776–1789
- Sowjanya KM, Swathi J, Narendra K, Krishna Satya. A review on phytochemical constituents and bioassay of Syzygium cumini International journal of natural product science 2013; 3(2): 1-11
- Ramya S. K Neethirajan, Jayakumararaj R. Profile of bioactive compounds in Syzygium cumini – a review. Journal of Pharmacy Research 2012,5(8),4548-4553
- Nighantu Ratnakar. Part 1, edited by Navre KR,notes of Panashikar VL and Soman KV. Choukhambha Sanskrit pratishan. Delhi.1st Ed,2011:87-88
- Helmstadter A. Syzygium cumini (L.) SKEELS (Myrtaceae) against diabetes –125 years of research. Pharmazie 2008; 63: 91–101
- Govind Das. Bhaishajya Ratnawali. Ed by R.D. Shashtri., Hindi Commentary. Choukhambha Prakashan, 18th Revised Ed, Varanasai .2007; 37: 719-742
- BhattA. Phytopharmaceuticals: A new drug class regulated in India. Perspect Clin Res.2016;7:59–61.